Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
Deprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients. Phenylethylamine and amphetamine have been investigated using a gas chromatographic technique.
D000662:Amphetamines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010627:Phenethylamines / Q000378:metabolism* / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D000662:Amphetamines; D010627:Phenethylamines; D012642:Selegiline